拉帕替尼

拉帕替尼联合硼替佐米抑制乳腺癌细胞生长及硼替佐米对拉帕替尼耐药细胞的活性的研究

Lapatinib in Combination with Bortezomib Inhibits Breast Cancer Cells Growth and the Activity of Bortezomib to Lapatinib-resistant Breast Cancer Cell

根据FDA提供的资料，拉帕替尼通过进入表达HER2蛋白的细胞，阻滞促进肿瘤生长的信号。

According to the FDA , Tykerb inhibits tumor growth by going inside cells containing the HER2 protein and blocking signals that promote tumor growth .

作为批准新上市的药物的一个标准程序，FDA将和药物开发公司撰写一个拉帕替尼的使用说明标签。

As is standard procedure with all new drug approvals , the FDA worked with the drug 's manufacturer to compose the instruction labeling accompanying Tykerb .

该研究发现拉帕替尼用于晚期乳腺癌患者的安全性与之前的临床研究一致。

Safety information from this study was consistent with previous Tykerb clinical studies in advanced breast cancer .

在批准的时候，拉帕替尼治疗的最终效果&长时间生存的观察目前还没有结果。

The ultimate impact Tykerb may have on long-term survival was still unknown at the time of approval .

然而通过该临床试验的结果就断定拉帕替尼能改善总生存率还为时过早。

It is too early to determine whether an improvement in overall survival will be observed in the clinical trial .

在头部和颈部局部晚期鳞状细胞癌患者中所进行的拉帕替尼联合放化疗的第一阶段研究。

Phase II , open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer .

这个研究结果表明：服用拉帕替尼和卡培他滨获得更为显著地治疗效果，延迟了肿瘤的生长。

That study revealed that women who took Tykerb in combination with capecitabine were significantly more likely to respond positively to treatment and to experience a delay in tumor growth .

这里存在一个问题：因为药物公司并没有设计进食中服用药物的试验研究，所以他们不能推荐拉帕替尼在进食过程中服用。

" Here 's the problem : Since the drug company didn 't do their trials with food , they can not recommend that their drug be given with food ," he said .